{"entity":{"id":"therorna","kind":"company","name":"Therorna","aka":["Yuanyin (Beijing) Biotechnology"],"tldr":"Therorna builds medicines from circular RNA, a more stable form of RNA. Its first cancer product is a therapeutic vaccine for people whose cancer is driven by the HPV-16 virus and has come back or spread.","summary":"Therorna Inc. (Yuanyin (Beijing) Biotechnology Co., Ltd.), founded in April 2021 according to the company, is based in Haidian District, Beijing, with a site in the Shanghai Free Trade Zone. It develops preventive and therapeutic medicines on a circular RNA (circRNA) platform. Its phase 1 dose-escalation study (NCT07081984) tests TI-0093, which the registry describes as a therapeutic tumour vaccine given by intramuscular injection on five occasions, in recurrent or metastatic HPV-16 positive solid tumours including head and neck squamous cell carcinoma and cervical cancer, at a site in Shanghai. Its first registered cancer trial, NCT07081984, was posted on ClinicalTrials.gov in July 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.therorna.com/"},{"label":"Company overview (Chinese)","url":"https://www.therorna.com/about.html"},{"label":"ClinicalTrials.gov: phase 1 trial of TI-0093 (NCT07081984)","url":"https://clinicaltrials.gov/study/NCT07081984"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-cervical-cancer","recurrent-metastatic-hnscc","hpv-positive-oropharyngeal-cancer"],"sections":["immunotherapy"],"technologies":["self-amplifying-rna","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding date and addresses from the company's Chinese 'company overview' and contact text, read on 29 October 2026.","The pages read do not state that TI-0093 itself is a circRNA product, although the company's platform is circRNA; this is an inference and should be checked.","Investors are not listed on the page read, and no financing amount was read."],"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.therorna.com/","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/therorna/","neighbours":{"cancer":[{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/"}]}}